Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.

Murphy GJ, Holder JC.

Trends Pharmacol Sci. 2000 Dec;21(12):469-74. Review.

PMID:
11121836
2.

Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.

Vázquez M, Silvestre JS, Prous JR.

Methods Find Exp Clin Pharmacol. 2002 Oct;24(8):515-23. Review.

PMID:
12500431
3.

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.

Berger J, Bailey P, Biswas C, Cullinan CA, Doebber TW, Hayes NS, Saperstein R, Smith RG, Leibowitz MD.

Endocrinology. 1996 Oct;137(10):4189-95.

PMID:
8828476
4.
5.

[Evaluation of a thiazolidinedione compound as a new antidiabetic drug].

Toyota T.

Nihon Rinsho. 2001 Nov;59(11):2211-8. Review. Japanese.

PMID:
11712410
6.

Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells.

Aoun P, Simpkins JW, Agarwal N.

Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2999-3004.

PMID:
12824244
7.

Novel insulin sensitizers: pharmacogenomic aspects.

Otto C, Lehrke M, Göke B.

Pharmacogenomics. 2002 Jan;3(1):99-116. Review.

PMID:
11966407
8.

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

Olefsky JM.

J Clin Invest. 2000 Aug;106(4):467-72. Review. No abstract available.

9.

Biology and toxicology of PPARgamma ligands.

Tugwood JD, Montague CT.

Hum Exp Toxicol. 2002 Aug;21(8):429-37. Review.

PMID:
12412636
10.

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF.

Diabetes. 2002 Apr;51(4):1083-7.

11.

PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?

Larsen TM, Toubro S, Astrup A.

Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61. Review.

PMID:
12586994
12.

Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?

Pershadsingh HA.

Expert Opin Investig Drugs. 2004 Mar;13(3):215-28. Review.

PMID:
15013941
13.
14.

Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione.

Iwata Y, Miyamoto S, Takamura M, Yanagisawa H, Kasuya A.

J Mol Graph Model. 2001;19(6):536-42, 598-600.

PMID:
11552681
15.
17.

[A role of the PPAR gamma activation in insulin resistance].

Yoshimasa Y.

Nihon Rinsho. 2001 Nov;59(11):2173-8. Japanese.

PMID:
11712403
18.

Insulin resistance and its treatment by thiazolidinediones.

Lebovitz HE, Banerji MA.

Recent Prog Horm Res. 2001;56:265-94. Review.

PMID:
11237217
19.

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines.

Jiang C, Ting AT, Seed B.

Nature. 1998 Jan 1;391(6662):82-6.

PMID:
9422509
20.

The mode of action of thiazolidinediones.

Hauner H.

Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S10-5. Review.

PMID:
11921433

Supplemental Content

Support Center